Levosimendaanin vaikutus systeemiseen ja splanknikusalueen verenkiertoon vatsa-aortan anyrysman vuoksi leikattavilla potilailla

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-002825-37-FI

Enrollment

Registered

2004-09-13

Start date

2004-11-08

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leikkaushoitoa vaativa elektiivinen aortta-aneyrymapotilas

Interventions

Trade Name: Simdax Product Name: Simdax Pharmaceutical Form: Intravenous infusion INN or Proposed INN: levosinmendaani Concentration unit: mg/ml milligram(s)/millilitre Concentration number: 2,5- Phar

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Vatsa-aortan aneyrysma Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Yliherkkyys levosimendaanille tai sen aineosalle

Design outcomes

Primary

Measure	Time frame
Main Objective: Levosimendaanin vaikutus systeemiseen ja splanknikusalueen verenkiertoon;Secondary Objective: Elinhäiriöiden ilmaantuvuus;Primary end point(s): Levosimendaanin vaikutus splanknikusalueen verenvirtaukseen	—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026